Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03088709 · ClinicalTrials.gov registry record · Phase 2
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
A Phase 2 study, sponsored by Loyola University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03088709: Clinical Trial Phase 2 study, sponsored by Loyola University.
NCT03088709 is a Phase 2 study that was terminated before completion, run by Loyola University. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03088709, a Phase 2 study, was terminated before completion, sponsored by Loyola University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Historically, the best results of allogeneic SCT have been obtained when the stem cell donor is a human leukocyte antigen (HLA)-matched sibling, however, this is only available for approximately 30 percent of patients in need for SCT. Alternative donor sources include matched unrelated donor utilizing the donor registry, cord blood transplant and mismatched donor transplant. A human leukocyte antigen (HLA)-haploidentical donor is one who shares, by common inheritance, exactly one HLA haplotype with the recipient, and includes the biologic parents, biologic children and full or half siblings. There is strong body of evidence supporting the use of haplo-SCT in patient who lack a matched sibling or unrelated donor with high rates of successful engraftment, effective Graft Versus Host Disease (GVHD) control and favorable outcomes comparative to those seen using other allograft sources, including HLA-matched sibling SCT. Furthermore, it provides a cost-efficient donor option in a timely manner especially for patients who need to proceed quickly to transplant due to concern of disease relapse/progression.
Primary Outcome
Blood test that measures amount of donor's cells
Interventions
- DRUG Cyclophosphamide
- DRUG Tacrolimus
- DRUG Mycophenolate mofetil
- OTHER Haploidentical Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-01-18 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 2 |
Why NCT03088709 stopped before completion
NCT03088709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT03088709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03088709 about?
NCT03088709 is a clinical study titled "Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide". Historically, the best results of allogeneic SCT have been obtained when the stem cell donor is a human leukocyte antigen (HLA)-matched sibling, however, this is only available for approximately 30 percent of patients in need for SCT. Alternative donor sources include matched unrelated donor utilizi...
What is the current status of trial NCT03088709?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-01-18. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT03088709?
The interventions under investigation include: Cyclophosphamide (DRUG), Tacrolimus (DRUG), Mycophenolate mofetil (DRUG), Haploidentical Stem Cell Transplantation (OTHER).
Who is sponsoring clinical trial NCT03088709?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03088709's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI